The Claim
Twenty-four weeks of rosuvastatin therapy in HIV-infected adults on antiretroviral therapy does not significantly change systemic expression of CD38 and HLA-DR on CD8+ T cells, despite reducing markers of vascular inflammation.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with HIV who are taking antiretroviral drugs, taking rosuvastatin for 24 weeks does not reduce the levels of CD38 and HLA-DR on CD8+ T cells, even though it lowers signs of blood vessel inflammation.
See the scientific wording
Rosuvastatin therapy for 24 weeks does not significantly alter systemic markers of immune activation such as CD8+ T-cell expression of CD38 and HLA-DR in HIV-infected adults on antiretroviral therapy, indicating limited impact on systemic T-cell activation despite reducing vascular inflammation.
Rosuvastatin blocks a cellular pathway that makes inflammatory molecules in blood vessel walls, which lowers inflammation in the arteries. This does not change the activation state of immune cells in the blood, because those cells are driven by different signals that rosuvastatin does not affect.
What the research says
1 studyTaking rosuvastatin for 6 months lowered a marker of blood vessel inflammation in people with HIV, but it didn’t lower the signs that their immune cells were still overactive — so it helped the blood vessels but didn’t calm down the broader immune system.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.